References in periodicals archive ?
In combination with our technologies for assessing behavior, PsychoGenics will be able to provide research support leading to the discovery of much needed new therapeutics.
Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for discontinued compounds such as Eltoprazine now in phase II trials for cognitive and motor disorders; as well as, early stage compounds with novel mechanisms of action.
PsychoGenics works with pharmaceutical and biotechnology companies, academic institutions, and not-for-profit research foundations to help discover treatments for such major neurological and psychiatric disorders as: ALS, anxiety, cognitive impairment, depression, Huntingtonos Disease, psychosis/schizophrenia, and Spinal Muscular Atrophy (SMA).
Another innovative experimental platform now available through PsychoGenics is the use of microdialysis in a behaving animal, which allows direct correlation of transmitter changes with ongoing behavior.
Under the agreement, PsychoGenics will use its proprietary drug discovery technologies to evaluate a number of AstraZeneca drug candidates for their potential to treat psychiatric disorders.
Overviews from awardees PsychoGenics and Gliacor Therapeutics were showcased in Q3 2012.
Lowe has more than 25 years of experience in pharmaceutical drug discovery and product development and an established track record of generating diverse clinical candidates and he will lead the drug discovery and development efforts at PsychoGenics.
Clinical work from PsychoGenics, in association with Lund University, studying eltoprazine as a treatment for levodopa-induced dyskinesias (LID) in PD.
SAN DIEGO and TARRYTOWN, New York, July 16, 2012 /PRNewswire/ -- Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
PsychoGenics Enters into Drug Discovery Agreement with Dainippon II-28
Recent Industry Activity II-25 Affymetrix Acquires USB Corp II-25 Roche Acquires Ventana Medical Systems II-25 Bruker BioSciences Acquires Bruker BioSpin Group II-25 Takeda Signs Agreement to Take Over Millennium II-25 Pfizer to Acquire Serenex II-26 Implant Sciences to Acquire Ion Metrics II-26 NascaCell and Archemix Expand Partnership for Aptamer-Based Drugs II-27 DiscoveRx and Cosmo Bio Sign Distribution Agreement II-27 Zydus Cadila Enters into Collaboration with Prolong Pharmaceuticals II-28 PsychoGenics Enters into Drug Discovery Agreement with Dainippon II-28 Zydus Cadila Collaborates with Karo Bio II-28 Nicholas Piramal's R&D Unit Extends Alliance with Eli Lilly II-29 Dr.